Oslo, 11 May 2022 - Targovax ASA announces that members of its executive
management team and key scientist are invited to present at upcoming
conferences:

33[rd ]Annual Cancer Progress Conference, virtual
Panel:  Victor Levitsky (CSO)
Panel title: Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old
-Fashioned Peptides - Is It the Target(s), Immunization Platform, Clin Dev
Strategy, or All of the Above?
Date: 11 May 2022
Time: 13:30 CET

Preclinical Immuno-Oncology, virtual
Presentation: Thomas B Hansen (VP Research)
Date: 18 May 2022
Time: 12:25 BST /13:25 CET

ABGSC Life Science Summit 2022, virtual
Presentation:  Erik Digman Wiklund (CEO)
Date: 19 May 2022
Time: 10:30 CET

8[th] Annual Immuno-Oncology Innovation Forum, virtual
Panel: Lubor Gaal (CFO)
Panel title: Optimizing the Inherent Combination Value of Oncolytic Viruses
Panel
Date: 25 May 2022
Time: 14:20 EDT / 20:20 CET

The presentations will be available on
www.targovax.com (https://www.targovax.com/en/presentations/) after the
conferences.

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.